study question: Can we develop an adequate preconception prediction model to identify those women with polycystic ovary syndrome (PCOS) who have an increased risk of developing gestational diabetes mellitus (GDM) during subsequent pregnancy? study answer: The risk of developing GDM in women with PCOS can be adequately predicted prior to conception by a prediction model. what is known already: Women with PCOS are at increased risk of pregnancy complications, especially GDM. GDM has serious short-term and long-term effects on mother and baby. study design, size, duration: This study is a part of a multicentre prospective cohort study, which was conducted between April 2008 and April 2012. A total of 326 women with PCOS were included.
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder worldwide in women of reproductive age, with a reported prevalence between 6 and 15% (Norman et al., 2007; Fauser et al., 2012) . PCOS is a heterogeneous reproductive disorder, which is diagnosed when at least two out of the three following criteria are present: oligoor anovulation, clinical or biochemical signs of hyperandrogenism and polycystic ovaries (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) . Associated features include obesity, impaired glucose tolerance, dyslipidaemia and metabolic dysfunction (Moran et al., 2010; Wild et al., 2011; Diamanti-Kandarakis and Dunaif, 2012) . Women with PCOS exhibit classical risk factors for cardiovascular disease (CVD) such as metabolic syndrome, type 2 diabetes, elevated CVD risk markers and are at increased risk of developing CVD at later age (de Groot et al., 2011; Toulis et al., 2011; DiamantiKandarakis and Dunaif, 2012; Fauser et al., 2012) .
In the past, multiple pregnancies frequently occurred due to multiple follicle development in women with PCOS during ovulation induction strategies. Multiple pregnancies exhibit an inherent increased risk of pregnancy complications compared with singletons (Fauser et al., 2005) . This problem, however, has been largely overcome with current low-dose ovulation induction regimens along with the introduction of single embryo transfer policies in IVF.
Even singleton pregnancies in women with PCOS are at increased risk for adverse outcomes as demonstrated by two recent meta-analyses and a large sample size population-based cohort study (Boomsma et al., 2006; Kjerulff et al., 2011; Roos et al., 2011) . These studies all disclosed increased complication rates in women with PCOS: e.g. gestational diabetes mellitus (GDM) [odds ratio (OR) 2.32 -3.66], pre-eclampsia (OR 1.45 -4.23) or pregnancy-induced hypertension (OR 3.67 -4.07) (Boomsma et al., 2006; Kjerulff et al., 2011; Roos et al., 2011) . Moreover, infants born from women with PCOS are at increased risk: e.g. premature birth (OR 1.75 -2.20), small for gestational age (OR 2.62) or large for gestational age (OR 1.39) (Boomsma et al., 2006; Kjerulff et al., 2011; Roos et al., 2011) .
The majority of studies included in the aforementioned meta-analyses were retrospective. The sample size of eight prospective studies undertaken so far was small (n ≤ 93) and included only pregnant women (Kjerulff et al., 2011) . It is therefore impossible to draw any conclusions from those studies with regard to preconception characteristics in relation to complications during pregnancy or delivery. To date, the only report relating preconception features to complications of pregnancy in women with PCOS was a recent preliminary report from our own group, demonstrating sex hormone-binding globulin (SHBG) concentrations as a predictor of GDM (Veltman-Verhulst et al., 2010) .
Feto-maternal healthcare would benefit from a tool able to predict GDM in women with PCOS before conception. Apart from PCOS, GDM has serious short-term and long-term effects on mother (e.g. metabolic syndrome, type 2 diabetes) and baby (large for gestational age, childhood obesity, metabolic syndrome) (Reece et al., 2009) . Women with PCOS could be classified in risk groups in order to offer them personalized periconception care. This could reduce unnecessary burden of intensified antenatal care and costs for low-risk women and focus screening programmes on women with PCOS, at high risk for pregnancy complications. Therefore, we aimed to develop a prediction model for GDM in women with PCOS before pregnancy.
Materials and Methods

Study design
This study is a part of the Copper study. The Copper study was conducted in four hospitals in the Netherlands between April 2008 and April 2012. Women diagnosed with PCOS, who visited the hospital because of a fertility disorder and who wish to get pregnant, were included in the study before conception. PCOS was diagnosed according to the Rotterdam 2003 consensus criteria following standardized phenotyping (Rotterdam ESHRE/ASRMSponsored PCOS Consensus Workshop Group, 2004; Goverde et al., 2009; Fauser et al., 2012) . Women were excluded in case of age ,18 years or .45 years, language barrier and type 1 or type 2 diabetes mellitus.
Ethical approval
This study was approved by the institutional review boards of all our participating centres. All women who participated in the study gave written informed consent. This study was registered with Clinicaltrials.gov, number NCT00821379.
Clinical assessments
All women underwent standardized preconception screening upon inclusion. This screening included a questionnaire concerning lifestyle, socio-economic status, mental state and family history of CVD and/or type 2 diabetes. Standard anthropometry (height, weight, waist and hip circumference), blood pressure and a transvaginal ultrasound scan of the uterus and ovaries (including antral follicle count) were performed by trained medical doctors. Metabolic and endocrine measurements, as previously described, were performed and analysed in each centre separately (Goverde et al., 2009) . All women underwent an oral glucose tolerance test (OGTT) according to our standard preconception protocol (75-g glucose load, 2 h follow-up).
Subsequently, most women started fertility treatment by ovulation induction because of oligo-or anovulation. In case of concurrent male factor infertility, intrauterine insemination, IVF or ICSI was performed. When pregnancy was achieved, patients were followed by antenatal care visits at 6 -8, 10 -12, 16 -18, 20 -22, 24 -26, 28 -30, 32 -34, 36 -38, 38 -40 and 40 -42 weeks of pregnancy and at 6 weeks post-partum. At each visit maternal blood pressure, body weight and a venous blood sample were obtained.
At 6 -8 weeks of gestation, a transvaginal ultrasound examination was performed to detect fetal heart activity and to measure the crown-rump length. Gestational age was determined by the best estimate according to the crownrump length, or the first day of the last menstrual period. At 24 -26 weeks of pregnancy, an OGTT (100-g glucose load, 3 h follow-up) was performed according to standard pregnancy protocol. Pregnancy outcome data were collected by a medical doctor after delivery.
Study outcomes
The aim of this study was to develop a prediction model for GDM. Secondary outcomes were other maternal complications and complications of labour and delivery.
Anticipated maternal complications besides GDM were pregnancy-induced hypertension, pre-eclampsia and the haemolysis elevated liver enzymes low platelets (HELLP) syndrome. GDM was defined as two or more plasma glucose levels exceeding a given threshold after a 100-g glucose load: fasting glucose ≥5.3 mmol/l, 1 h glucose ≥10.0 mmol/l, 2 h glucose ≥8.6 mmol/l and 3 h glucose ≥ 7.8 mmol/l (American Diabetes Association, 2003). Pregnancy-induced hypertension was defined as a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg. Pre-eclampsia was defined as pregnancy-induced hypertension and proteinuria (≥300 mg/ 24 h). Neonatal outcomes were (spontaneous or induced) premature birth which was defined as gestational age ,37 weeks, small for gestational age as birthweight ,10th percentile for gestational age and gender, large for gestational age as birthweight .90th percentile for gestational age and gender and hypoglycaemia as a glucose value ,2.6 mmol/l. Complications of labour and delivery were assisted vaginal delivery (vacuum extraction or forceps), Caesarean section, post-partum haemorrhage, signs of intrauterine infection during delivery, shoulder dystocia and placental retention. Post-partum haemorrhage was defined as .1000 ml blood loss per 24 h within 6 weeks post-partum and placental retention as a situation after delivery in which placental delivery does not occur within 1 h. A shoulder dystocia was defined as a situation after delivery of the head of the neonate, when the indentation of the shoulder within the maternal pelvis prevents further delivery.
Statistical analysis
All data were collected in a database using SPSS Statistics (IBM SPSS, Inc., Chicago, IL, USA version 20.0). In the dataset, several women had missing data at random and for some laboratory measurements selective missing (up to 60%) may have occurred, due to insufficient compliance to the study protocol of some hospitals. To avoid any potential bias that might have occurred, multiple imputation (10 times) was applied using observed baseline characteristics and the outcome data, though the outcome itself was not imputed. Missing baseline data were imputed using a logistic regression model that included the variables given in Table I (Sterne et al., 2009) . We compared baseline characteristics in women who developed GDM with women who did not, x 2 tests were used to calculate P-values for the categorical variables and Mann-Whitney U-tests were performed on the continuous variables. Associations between baseline characteristics and GDM were calculated by univariate and multivariate logistic regression analyses. After univariate regression, variables with P ≤ 0.15 were put in a multivariate logistic regression model using backward elimination with P . 0.15 to determine the predictive strength of these variables for GDM. For a single model parameter, a critical P value of 0.15 is equivalent to using the broadly accepted Akaike's information criterion as model selection method (Akaike, 1973) . The prediction model was tested using the area under the curve (AUC) of the receiver-operating characteristic (ROC). To assess the amount of overfitting, inherently present in analyses such as these, bootstrapping with 200 replications was used, which produced a shrinkage factor on the regression coefficients (Van Houwelingen and Le Cessie, 1990) . Moreover, the optimism in the AUC was determined and an optimism-corrected AUC was subsequently calculated. For ease of use, the prediction model was presented as a score chart. The score chart was developed in R 3.0.0 by the normogram function in the RMS library.
Results
A total of 326 women with PCOS were included, of which 214 women got pregnant. The pregnancies of 189 (88%) women continued beyond a gestational age of 20 weeks and were followed intensively. Their features and outcomes are summarized in Table I . The remaining 25 pregnant women miscarried and were excluded from further analysis. The 189 women delivered 206 children, since there were 15 twins and 1 triplet pregnancy. A total of 62 (33%) women experienced 1 or 2 maternal complication(s). GDM alone occurred in 41 (22%) women, pregnancy-induced hypertension in 14 (7%) and pre-eclampsia in 8 (4%) women. Neonatal complications occurred in 49 (26%) infants. Ninety-one (48%) women had a complication of labour. Table I shows differences in features comparing women who developed GDM versus women who did not; among other changes preconception BMI, waist circumference, systolic blood pressure and fasting glucose were significantly higher and SHBG was significantly lower in women who developed GDM.
After univariate and multivariate logistic regression analyses, the following variables turned out to be statistically significant independent predictors for GDM (Table II) : type 2 diabetes in first-degree relatives (OR 3.87, 95% CI 1.21 -12.38), fasting glucose (mmol/l) (OR 3.58, 95% CI 1.28 -10.03), fasting insulin (mU/l) (OR 1.16, 95% CI 1.05 -1.28), androstenedione (nmol/l) (OR 0.77, 95% CI 0.66 -0.90) and SHBG serum concentration (nmol/l) (OR 0.98, 95% CI 0.96-1.00). The ROC curve in Fig. 1 shows the predictive strength of these preconception risk factors for GDM, with an AUC of 0.87 (95% CI 0.81-0.93).
The probability of developing GDM can be calculated using Table III  and Fig. 2 . A total score can be calculated by adding the subscores for the five screening predictors in Table III . The total score can be matched to a probability of developing GDM in Fig. 2 .
The shrinkage factor on the regression coefficients after bootstrapping was 0 . 81 and the optimism corrected AUC was 0.83 (95% CI 0.77 -0.89). The histogram and boxplot in Fig. 3 show the distribution of the predicted probabilities of our model for women with PCOS to develop GDM.
Discussion
The current study represents the largest prospective follow-up regarding pregnancy complications in anovulatory infertile women diagnosed with PCOS. Since women with PCOS were screened in a standardized fashion before conception, we were able to assess whether features upon initial screening could predict GDM. , 2010) . The risk of pregnancy complications might be reduced due to the relatively low incidence of obesity; however, we found a remarkably high incidence (22%) of GDM in our study group. Obesity (BMI ≥ 30 kg/m 2 ) contributes to the high risk of GDM and one study showed a presence of 37% in the women diagnosed with GDM (Ghazeeri et al., 2012) , whereas only 20% of our total study group was obese. The incidence of GDM in other prospective studies in women with PCOS reported so far varied from 8 to 16% (Bjercke et al., 2002; Palomba et al., 2010) . However, these studies involved much smaller sample sizes, and other studies were retrospective (Kjerulff et al., 2011) . In healthy women, GDM occurred in 1-5% of all pregnancies (Shand et al., 2008; Roberts et al., 2011) .
Multiple pregnancies occurred in 16 (8%) of the women. Multiple pregnancies have an increased risk of pregnancy complications compared with singleton pregnancies (Fauser et al., 2005) . We decided not to exclude multiple pregnancies in our study, because we aimed to develop a prediction model based on patient characteristics before conception, prior to knowledge about the occurrence of a multiple pregnancy. Post hoc, it appeared that only 1 of the 16 multiple pregnancies was complicated with gestational diabetes, thus it would not have made a large difference to exclude them from analysis.
The observed pregnancy-induced hypertension rate in the current study was relatively low (7%). Previous studies in women with PCOS reported an increased incidence of pregnancy-induced hypertension ranging from 8 to 27% (Bjercke et al., 2002; Sir-Petermann et al., 2005; Hu et al., 2007; Palomba et al., 2010) . In contrast, pregnancy-induced hypertension occurred in 4-9% of healthy pregnant women (Bhattacharya et al., 2007; Shand et al., 2008; Liu et al., 2011; Roberts et al., 2011) . The broad range of the reported incidence of pregnancy-induced hypertension in studies in women with PCOS could be explained by the bias which may have occurred because of the small sample sizes, the inclusion of women who were already pregnant or the retrospective designs.
Our study was unable to identify an increased incidence of pregnancy-induced hypertension in women suffering from PCOS, which may be related to the relatively low BMI in our study population.
The most common neonatal complication in this study was premature birth (12%), a third of which (4%) was due to induction, possibly reflecting the high GDM rate in this population. The incidence of preterm birth reported in a meta-analysis on pregnancies in women with PCOS was 14%; however, no differentiation was made between spontaneous and induced premature birth (Kjerulff et al., 2011) . The reported undifferentiated premature delivery incidence in neonates of healthy women ranged from 5 to 8% (Bhattacharya et al., 2007; Shand et al., 2008; Roberts et al., 2011) .
Despite the high number of women with GDM in our study, only 2% of the neonates were large for gestational age, although 16% of neonates in a meta-analysis regarding pregnancies in women with PCOS were large for gestational age (Kjerulff et al., 2011) . In healthy women, 10 -12% of the neonates were large for gestational age (Shand et al., 2008; Liu et al., 2011) . A possible explanation for the low number of large for gestational age neonates observed in our study group might be that glucose levels were better regulated compared with other studies. In the Netherlands, women with GDM are intensively monitored and adequately treated (by e.g. diet, insulin, metformin). Moreover, the definition of GDM has always been a subject of discussion. WHO criteria from 1999 and older were used by some studies, which described higher threshold values for diagnosing GDM compared with the criteria we used as postulated by the American Diabetes Association (American Diabetes Association, 2003; Palomba et al., 2010) . Another explanation might be that our study population was relatively lean.
We aimed to develop a prediction model for one of the most common pregnancy complications in women with PCOS, GDM. Predictors in our multivariate prediction model were first-degree relatives with type 2 With GDM (n 5 41)
P-value
Instrumental delivery (vacuum, forceps) 32 (17) 27 (18) 5 (12) Caesaean section 45 (24) 33 (22) 12 (29) Haemorrhage post-partum 13 (7) 10 (7) 3 (7) Other (placental retention, infection, shoulder dystocia) 6 (3) 6 (4) 0 Data are median [IQR] or number (). The following variables are used for analysis, but not shown in the table: diet, alcohol, dehydroepiandrosterone, type 2 diabetes and CVD in second-degree relatives and age at menarche. BMI, body mass index; CVD, cardiovascular disease; GDM, gestational diabetes mellitus; IVF/ICSI, in vitro fertilisation/intracellular sperm injection; LH, lutenising hormone; PCOS, polysystic ovary syndrome. In some subjects ≥1 complication occurred. Total number of subjects with a complication.
e All women in this group had GDM as a complication.
diabetes, fasting glucose, fasting insulin androstenedione and SHBG serum concentrations. We were able to identify women at risk for GDM with an 83% precision. A score chart involving the abovementioned screening characteristics has been designed to calculate the GDM risk for a given woman. Interventions were not performed in this study. The predicting variables androstenedione and SHBG seem associated with the development of GDM (American Diabetes Association, 2003) . A total score can be calculated by adding the subscores for each screening parameter together. The score can be matched to the risk chart (Fig. 2) in order to obtain a predicted probability for a woman to get GDM. For example, a woman with PCOS had no first-degree relatives with type 2 diabetes, a glucose of 5.1 mmol/l, an insulin of 12.0 mU/l, an androstenedione of 8.3 nmol/l and a SHBG of 25.0 nmol/l. Scores are 0 for first-degree relatives with type 2 diabetes, 6 points for glucose, 5 for insulin, 15 for androstenedione and 12 for SHBG. The total score is 38, with a predicted probability to get GDM of 42%.
Figure 2 Score chart and the preconception probability for women with PCOS to get GDM. Figure 3 Histogram to show the distribution of predicted probabilities to get GDM based on first-degree relatives with type 2 diabetes, fasting glucose, fasting insulin, androstenedione and SHBG. Inset, boxplot of predicted probability of GDM by true GDM status.
As previously reported, SHBG could be a marker of insulin resistance in vivo, because of the inhibition of SHBG secretion in the human hepatoma cell line in vitro by insulin (Plymate et al., 1988) . In addition, earlier findings in a small subgroup of the current study (50 first included women) showed that GDM is associated with lower SHBG levels (OR 0.92, 95% CI 0.87-0.97) with a predictive precision of 86% (VeltmanVerhulst et al., 2010) . This study was based on a smaller number of patients and no internal validation was performed and so no correction for optimism was applied. Indeed, in the current data the corrected AUC for SHBG solely was 0.74 (95% CI 0.66 -0.82), which is considerably lower than in the previous study, but also much lower than the AUC of the model with five predictors. The association between low androstenedione concentrations and GDM remains unclear. However, hyperandrogenism is an important feature of PCOS and hyperinsulinaemia, observed in many women with PCOS, increases the bioavailability of androgens (Rajkhowa et al., 1994) .
The main points in the current study are its prospective design starting before conception, the considerable sample size and the standardized collection of determinants and outcomes. Another limitation is some missing data for the determinants, which were accounted for by multiple imputation. Multiple imputation is preferred over complete case analysis when missing data are at random (Donders et al., 2006) . Furthermore, we might have overestimated the incidence of GDM in a small proportion of women, since we used the preferred glucose load (100 g) for diagnosing GDM with the OGTT according to the American Diabetes Association in 2003 (American Diabetes Association, 2003 . Shortly after this study ended, a new guideline of the American Diabetes Association appeared which recommended to use a 75-g OGTT with the same cut-off points as the 100-g OGTT (American Diabetes Association, 2012). With the 75-g OGTT women with moderate glucose intolerance will not be classified as GDM and so we speculate that the performance of our prediction model would then even improve. It would therefore be very interesting to perform an external validation of our prediction model in future studies in women with GDM based on the new ADA guidelines.
In conclusion, the current study confirms that women with PCOS exhibit an evident increased risk of developing GDM and premature delivery. In contrast to other studies in women with PCOS, the observed incidence of pregnancy-induced hypertension, pre-eclampsia and small for gestational age infants did not seem to be increased. We developed a prediction model able to identify accurately women with PCOS at risk for GDM before conception. Such women should be monitored closely during pregnancy, with frequent glucose evaluation and interventions if needed. This will enable preventive measures that may reduce the risk of developing GDM or enable early detection of GDM to reduce adverse consequences. For future research purposes, a combined prediction model for GDM could be created with a preconception prediction and an adjusted prediction during pregnancy in order to improve our prediction model. Moreover, further research is needed to determine intervention strategies based on the calculated risks for women with PCOS. and interpreted the data and wrote the manuscript. B.C.J.M.F. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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